Join us on August 22–23, 2026 at the Grand Hyatt Indian Wells
Join us on August 22–23, 2026 at the Grand Hyatt Indian Wells
Dr. Renato Saltz opened the keynote with his own journey from academic reconstructive surgery to aesthetic medicine, recalling how changing patient expectations, new technologies, and the emergence of nonsurgical treatments pushed him to rethink what a plastic surgery practice could be. When his vision for integrating aesthetic surgery with a medical spa was not embraced within his academic institution, he built it himself, an experience that shaped many of the lessons he shared from more than two decades in practice. His model centers on creating “patients for life” through comprehensive treatment plans that connect surgical care, nonsurgical procedures, skin care, and pre- and postoperative support rather than treating each visit as a single transaction. He stressed that sustainable growth depends just as much on the team as the physician: everyone should understand what the practice offers, communicate consistently, and stay focused on patient satisfaction and safety. Regular staff meetings, sharing new learning with the team, maintaining a clear organizational structure, and keeping a close eye on patient experience and practice financials were among his practical tips for staying organized and accountable. He also urged practices to resist complacency, continually evaluate new treatments and technologies, know their financials and referral sources, and adapt when the market changes. Branding and social media should reflect something authentic that genuinely defines the physician and practice, rather than simply following trends; for Dr. Saltz, highlighting his expertise in endoscopic surgery allowed his online presence to grow organically around what made his practice distinctive. Even as aesthetic medicine expands rapidly, he cautioned that growth cannot come at the expense of safety or quality. His final challenge was more personal: define what success actually means to you. For him, after decades of building and evolving a practice, it comes back to happy patients, a happy practice, and a life that remains fulfilling beyond the business itself.
Julie Frost opened by reframing the aesthetic client experience through the lens of psychology, arguing that a client’s vulnerable decision to seek treatment begins long before they walk in the door and must be supported by a “wow” digital first impression, a five-senses-engaging front office (sight, smell, taste, sound, touch), and consistent follow-through after the consultation—since follow-through, not follow-up, is where most practices lose retention. She introduced the cosmetic interest questionnaire as a “permission slip” that reveals a client’s full range of concerns beyond the single treatment they booked, enabling providers to build a long-term aesthetic roadmap rather than a one-off transaction, and outlined her “Six Rs of Rejuvenation” assessment framework (relax, recontour, reposition, reduce, resurface, rejuvenate) alongside the LAER consultation model (Listen, Acknowledge, Explore, Respond), emphasizing that 80% of consultation time should be spent listening and acknowledging rather than immediately problem-solving. She then walked through her practice’s customized 12-month treatment plan builder—a software tool that generates itemized packages with calendar-based scheduling, VIP discounts, and flexible payment plans in real time with the client—paired with a provider-level follow-up dashboard that tracks conversion rates, average package value, and automated day-3/10/30 outreach, positioning both the luxury consultation folder and the digital retention engine as key drivers of client loyalty and revenue growth.
Izhak Musli framed patient retention as the true competitive battleground in aesthetics, arguing that between two practices treating the same patient, the differentiator is not marketing or clinical skill but retention strategy, and cited industry data showing the average practice loses 50% of patients after their first visit despite spending heavily to acquire them—the “leaky bucket syndrome” that prevents practices from ever compounding growth. He walked through the full patient journey and its common failure points, stressing that leads must be called back within five minutes to create a “wow factor,” that every visit must end with the next appointment booked in-room before checkout (since deferring booking to the front desk or the patient’s own follow-through cuts rebooking rates roughly in half), and that providers must treat maintenance as ongoing education rather than an upsell, selling a 12-month treatment plan rather than a single transaction. He distinguished functional loyalty from “emotional conversion”—using examples like iPhone’s blue bubble and Starbucks cups—arguing that practices should build identity-level attachment so patients want to share and refer, and cautioned against under-tracked liabilities like beauty banks and gift cards, discount-based rewards, and unstructured referral incentives, recommending appreciation-based rewards (handwritten notes, points programs) instead. He closed with six core KPIs practices should review weekly (retention rate, rebooking rate, referral rate among them), a 30/60/90-day action plan for implementing treatment-plan templates and rebooking workflows, and a pitch for his patient-retention platform, Get Kudos AI, built to automate reminders, reviews, and referral tracking.
Terri Ross opened with a blunt call to reframe the med spa business as fundamentally a sales operation, arguing that clinical skill alone is a commodity and that the consultation is the single highest revenue-generating event in a practice, since patients who will not pay for a consultation won’t pay for a treatment plan either. She emphasized that sales is fundamentally “a transfer of emotion,” coaching providers to stop rushing into diagnosis-and-treatment lists and instead use the layer method (listen, acknowledge, explore, respond) to uncover the emotional driver behind a patient’s concern—insecurity, a divorce, a return to dating—so the eventual treatment plan is framed around a felt outcome (confidence) rather than a price tag. She cited data showing 86% of patients want a pre-treatment plan and 91% want a post-treatment plan, yet fewer than half of practices deliver either, and stressed that most practices don’t know their own core KPIs (revenue per hour, conversion rate, average patient spend), leaving providers unable to identify where money is being left on the table. She closed by warning against discounting and reactive marketing spend as substitutes for consultation mastery, sharing a client example of a $300K revenue increase driven purely by better treatment-plan bundling, and urged attendees to audit their own numbers, invest in real sales training for their teams (especially front desk staff), and treat every patient interaction as an opportunity to build lifetime-value relationships rather than one-off transactions.
Dr. Patel distinguished cosmetic-grade from cosmeceutical-grade raw materials, noting purity matters little for surface-only products but becomes critical once a formulation actually penetrates skin and engages cellular receptors. He described a proprietary peptide delivery system that stabilizes and miniaturizes peptides to bypass the stratum corneum and bind target receptors via “lock-and-key” specificity, patented across multiple applications. His approach to skin aging centers on three drivers—oxidative stress, mitochondrial dysfunction, and inflammation—and he was critical of most commercial antioxidants (including vitamin C, which can act as a pro-oxidant), arguing true efficacy requires mitochondrial-level glutathione support (with cysteine as the rate-limiting amino acid) rather than superficial topicals. He highlighted GHK-Cu, a copper-binding plasma-derived peptide used by the body for wound healing, whose age-related decline underlies much of the high-cost aesthetic industry, stressing that no single ingredient solves skin aging. Effective regimens need a synergistic, multi-product ecosystem paired with dietary amino acids (glycine, proline, lysine) to support endogenous collagen production. He closed by detailing manufacturing standards (a metal-free facility, an experienced formulation chemist) and a trial comparing his GHK-copper serum against topical retinol, showing measurable improvement. He framed his product line as a layered support system: serum driving results, paired with moisturizing creams and roughly 19 supporting actives (including CoQ10 for mitochondrial energy) addressing oxidative stress, glycation, and inflammation together.
The speaker framed skin rejuvenation as rebuilding the dermal foundation, noting that collagen declines roughly 1% per year after age 25, so that by the forties fibers have fragmented and disorganized and the skin begins to descend. She positioned Sofwave as distinct from focused ultrasound because it delivers seven parallel, non-focused beams rather than converging energy at a point. The core concept is thermal selectivity: at 11.5 megahertz, energy is preferentially absorbed by dense dermal collagen, so heating begins around 0.5 millimeters deep regardless of dermal thickness or treatment site. Integrated cooling holds the epidermis near 36 degrees Celsius while the dermis reaches 65 degrees, where collagen remodels. Importantly, because absorption depends on tissue composition rather than a set focal depth, the energy does not reach subcutaneous fat — a meaningful differentiator from devices that risk fat loss. She reviewed seven FDA clearances spanning wrinkles, acne scars, cellulite, eyebrow lifting, and neck laxity, noting these reflect substantial equivalence rather than proven superiority. On evidence, she highlighted what she described as the longest published histologic follow-up in the category, with biopsies at ten months showing roughly 60% more collagen and over 30% more elastin. She described old collagen clearing near four weeks and the visible result emerging around twelve weeks as fibroblast activity peaks, with continued improvement through twenty-four weeks. Practically, it is a 35 to 40 minute treatment with no downtime that can be delegated, since results depend on a target total energy per area rather than operator technique. Notably, she reported quantitative measurement showing volume restoration in some patients despite volumizing not being a treatment goal.
The speaker positioned the 2910 nanometer cold fiber laser as a new category in resurfacing, distinct from fully ablative and fractional CO2 devices. Its defining feature is that fiber technology delivers roughly 95% ablation with only about 5% coagulation, so the skin is not heated the way it is with conventional resurfacing — which she identified as the source of the post-inflammatory hyperpigmentation risk that has historically limited these devices. Because of that, she described it as safe across all skin types, a point she emphasized as practice-changing in South Florida, where months of sun avoidance after fractional CO2 is unrealistic for most patients. Other design differences include one of the smallest spot sizes available at roughly 170 microns and delivery of energy in four micropulses rather than a single pulse, which keeps the skin from overheating. Downtime is minimal, with even aggressive treatments recovering in about five to seven days, and treatments run from 10 to 15 minutes superficially up to 30 to 40 minutes for deeper work. She noted that the most superficial mode treats only the stratum corneum yet still produces measurable pigment improvement and collagen stimulation. Notably, the feature she considered unique is Laser Coring, in which three to six pulses of the deep mode create a corkscrew pattern of cores in the skin, producing tissue contraction and improvement in superficial laxity and fine lines that she felt matched or exceeded fractional CO2. She also emphasized that results are reproducible rather than operator-dependent, with consistent outcomes across her physician assistants. She uses it in younger patients for acne scarring, dyschromia, and early photoaging, and in middle-aged patients for periorbital rhytides and laxity, adding that it provides the most skin tightening of any resurfacing laser she has used.
Marc framed aesthetic medicine as a field where practices must compete for attention to bring patients in and then deliver results to keep them, since these patients come by choice rather than through insurance networks. He opened by noting new California legislation restricting trichloroacetic acid that takes effect January 1, emphasizing that it is unusually broad in that it applies regardless of concentration, application, or provider credential. The bulk of the talk was a scorecard framework borrowed from medical device development, intended to give clinicians a structured way to evaluate any new modality. He built it on three legs: improving clinical outcomes, supporting sustainable practice economics, and enhancing the client experience. Under outcomes he asked what breadth of cases a product addresses, which skin types it serves, and what seasonality constraints apply. Under economics he asked about retail price, margin, inventory, reordering flexibility, and daily operations, noting that operational fit is the criterion most often overlooked. Under client experience he asked what the treatment feels like for the patient, what it demands in time and downtime, and whether it generates referrals. Notably, the scoring method was his central practical contribution: first weight each category for importance to your own practice and zero out anything scoring one or two, then score the remaining categories using only one, three, or five rather than the full scale, which forces meaningful separation instead of false precision. He closed by urging that regulatory pressure should not become a reason to accept a lesser product.
The speaker noted that most practices are already using AI whether or not they chose to, since EMR vendors, recall services, and marketing companies are all layering it into their products. He framed the risk across your team, your vendors, and your business, noting the most common exposure is mundane — a staff member dropping a report with the medical record number attached into a chatbot. He emphasized that a medical record number is protected health information, and that de-identification means more than deleting a patient’s name. He also flagged meeting auto-recorders as an underappreciated hazard, since they often run without the host realizing it. Importantly, he argued the greater risk for most practices is not compliance exposure but failing to use tools they should be using. He described drafting and summarizing as useful but never publishable without review, and recommended deep research for payer policy and competitor analysis, since Medicare data and contracted rates are publicly available. He also suggested dropping several years of profit-and-loss data into a model to identify where expenses sit and which costs are fixed versus variable. Notably, he offered a short vendor vetting protocol: are you using AI on my data, where is it stored, do I have a business associate agreement with any third parties, who reviews the output, and — the question he considered most important — when and where are humans involved. He noted that essentially none of his own customers have ever asked him these questions, and closed by advising that compliance and security still require real engineering.
The speaker argued that most physicians build strong clinical teams but have no coordinated financial team, with an accountant, attorney, and financial planner who rarely speak to one another. He distinguished a CPA, whose role is annual compliance, from a tax strategist, who meets quarterly and works proactively to identify provisions a practice qualifies for. The provision he emphasized most was the Augusta Rule under IRC Section 280A(g), which allows a business owner to rent their personal residence to their business for up to 14 days per year for meetings or corporate events, with the rental income excluded from personal taxable income while remaining deductible to the business. He also described R&D tax credits as available to business owners doing innovative work, noting they offset tax dollar for dollar and do not expire. On asset protection, he outlined asset protection trusts and Nevada series LLCs as structures for holding assets outside personal ownership, and cautioned that transferring assets after a lawsuit is filed constitutes fraudulent conveyance.
Speaking as the founder of his own skincare line, the speaker argued that most product failures begin not with a bad product but with a founder who fell in love with an idea before ever meeting a customer. He nearly made that mistake himself, having developed a formula, name, and packaging before a business school professor asked whether he had established product-market fit — a term he did not yet know. He stopped and spent roughly $10,000 on a focus group, learning not only that the need was real but what customers thought about texture, pricing, and messaging, which framed his central lesson that every decision should be data-informed. He organized the process into six moves, beginning with finding your fit before you formulate: identify the white space, name the specific person who needs the product, and accept the trade-off of cutting customers, because when you speak to everyone you speak to no one. Second, build your bench — a cosmetic chemist from day one, a manufacturer who knows your niche, confirmation that you own your formula, and a regulatory consultant. Third, get launch ready through consumer perception, clinical, stability, and microbial testing, noting that sunscreens are regulated as over-the-counter drugs. Fourth, position yourself so it sticks, then keep learning from customers and collecting data. Fifth, earn the channel by choosing distribution deliberately, cautioning against moving into large retailers too quickly and leaving room if acquisition is the goal. Notably, he offered a positioning template worth memorizing — for a given customer, this brand is the category that delivers a specific point of difference, because of a stated reason to believe.
Organized marketing into four stages: fascination, acquisition, conversion, and retention. Fascination is simply getting eyeballs on the business, and he emphasized surrounding your market rather than relying on one channel — using the example of a customer hit by email, social, and a pre-roll ad before a friend suggests coffee, at which point the choice is already made. Importantly, he cautioned that much of what practices attribute to word of mouth is actually their own content doing the work upstream, noting that when he increased his posting substantially his leads tripled even though almost none came directly from social. Acquisition means converting attention into contact information — first name, last name, email, and phone — typically through a lead magnet such as a modest offer toward a first appointment, with a website conversion target of roughly five to eight percent. Conversion means getting patients into the chair, for which he stressed calling leads quickly, noting that an immediate callback substantially raises the chance of connecting, and setting a lead-to-appointment target around 55 percent tracked through a CRM. Retention, he said, is the stage almost nobody measures, and he advised starting with rebooking rate as the simplest metric to track daily.
The talk organized around four A’s: authenticity, accountability, aftercare, and AI. On authenticity, both agreed that follower count does not equal influence — the brand side emphasized leading with education and selling second, staying in your own voice rather than becoming a different person online, and building trust by posting consistently even when engagement disappoints, while noting that their strongest partnerships began organically with practitioners already using the products. Dr. Sugai added that brand sponsorships should never alter clinical judgment, and that what you say online must match what you say in the exam room. He cautioned against fear-mongering hooks and creators who obscure their credentials, arguing it should take only a couple of clicks to verify that someone is a licensed professional. On accountability, he offered a three-question checklist before posting — is it true, is it useful, and could it hurt anyone — and reflected candidly on receiving criticism, including from colleagues, making the point that a post can be genuinely worth criticizing while the creator still does not deserve harassment. On aftercare, both pushed back on the worry about seeming pushy, reframing product recommendations as prescribing a routine rather than moving inventory, and noting that recommending products you do not sell is what actually builds patient trust.
Dr. Apple Bodemer challenged the idea of skin as simply a barrier, describing it instead as an active endocrine organ that both responds to circulating hormones and produces hormones locally. She emphasized that estrogen, androgens, cortisol, vitamin D, thyroid hormones, insulin, and other hormonal pathways work together to influence hair cycling, collagen, wound healing, sebum production, pigmentation, inflammation, and barrier function. This local activity also helps explain why a patient can have apparently normal serum hormone levels while still showing hormone-driven changes in the skin or hair. The practical message was to recognize when a dermatologic complaint deserves a deeper look. Treatment-resistant acne, hirsutism, irregular menstrual cycles, early or rapidly progressive patterned hair loss, acanthosis nigricans, and other signs of androgen excess or metabolic dysfunction may warrant further evaluation rather than another skin-directed treatment alone. Menopause was another key example: declining estrogen affects collagen, hydration, barrier function, wound healing, and hair cycling, while topical estrogen is an emerging area of interest but still has limited data. Dr. Bodemer also highlighted insulin resistance as an important metabolic factor affecting the skin. She explained that elevated insulin and insulin resistance can develop well before glucose or hemoglobin A1c reflects the problem, and uses fasting glucose and fasting insulin to calculate the homeostatic model assessment of insulin resistance when clinically appropriate. Her takeaway was practical: not every skin concern needs a hormone workup, but recognizing the red flags, and addressing or referring for underlying hormonal and metabolic drivers, may improve both skin health and aesthetic outcomes.
Dr. Johnny Franco approached aesthetic technology through the idea of a treatment journey rather than a single device or procedure. With more patients experiencing significant weight loss, often at younger ages, he emphasized first identifying what has actually changed, skin laxity, volume, surface quality, cellulite, and body contour, and determining which concerns may respond to nonsurgical treatment and which still require surgery. A recurring theme was the value of starting the conversation early. Rather than waiting until patients finish losing weight to address aesthetic changes, he discussed being proactive while setting realistic expectations, particularly because skin tightening remains an active process while weight loss is ongoing. Instead of relying on one technology, he encouraged thinking in layers and combining approaches to address skin laxity, volume, cellulite, and other concerns based on what will make the greatest difference for that individual patient. Dr. Franco also stressed the importance of giving patients a clear roadmap. In his practice, treatment plans may be mapped over six, nine, or twelve months, prioritizing what matters most while allowing additional treatments to be added over time. He emphasized that the entire office team should understand that journey so patients receive consistent guidance from consultation through follow-up. His closing advice was to evaluate each layer of the concern, recognize that nonsurgical options continue to expand, and build a thoughtful treatment plan rather than treating what may be only one part of the problem.
Yvonne Dellos delivered a deeply personal talk on presence and leadership in aesthetic practice, opening with her own story of homelessness at age 14 and finding stability through a nurse practitioner, who saw her as a person rather than a chart—an encounter she credits with changing the trajectory of her life and shaping her belief that providers are “building people, not businesses.” She illustrated this philosophy through a story about a young model who came in for lip filler at her mother’s suggestion, describing how sitting fully present with the patient revealed the emotional weight behind a seemingly cosmetic request, and framed the resulting transformation as a privilege to alter someone’s self-image rather than a transaction. Drawing on this experience, she argued that leadership is defined by behavior and energy rather than title, using an anecdote about coaching a colleague through team friction to make the point that presence and “essence” communicate far more than words, and encouraged the audience to treat every patient and colleague interaction as an act of service and influence. People’s feelings after an encounter, not clinical volume or revenue, is the true measure of a practice’s success and legacy.
Dr. Adriana Cruz introduced the integration of lifestyle medicine into aesthetic dermatology, asserting that because we treat living, communicating tissue rather than static wrinkles, procedural outcomes and tissue repair are heavily dictated by the patient’s underlying biology. While genetics dictate only about 20% of skin aging, the remaining 80% is driven by the exposome—the cumulative lifetime impact of exposures, environmental factors, and lifestyle decisions. To optimize clinical results, she detailed the six interconnected pillars of lifestyle medicine: shifting from a Standard American Diet (which triggers glycation, dysbiosis, and chronic low-grade inflammation) to a whole-food, plant-based Mediterranean diet; prescribing physical activity (both aerobic and resistance training to stimulate exerkines like irisin, which improve elasticity and dermal structure); regulating stress (mitigating HPA axis and cortisol spikes that impair wound healing and barrier function through mind-body practices like meditation); prioritizing restorative deep and REM sleep to support tissue recovery and metabolic washout; eliminating deleterious exposures such as sun, pollution, tobacco, alcohol, and prescription misuse; and fostering strong social connections to lower biological stress. Ultimately, she urged aesthetic providers to look beyond the needle and build collaborative, multidisciplinary teams that address these systemic physiological factors to enhance wound healing, tissue regeneration, and long-term treatment results.
Dr. Martha Viera presented a multi-pronged clinical protocol to treat resistant and relapsing melasma, highlighting that it is a chronic, multifactorial inflammatory disease characterized by melanocyte hyperactivity, solar elastosis, mast cell activation, and increased dermal vascularity. In a case series of 10 female patients with skin types III and IV, she demonstrated the efficacy of a dual-injection protocol that delivers hyperdiluted botulinum toxin and tranexamic acid intradermally as separate, sequential treatments to achieve optimal pigment breakdown without local side effects. Mechanistically, her micro-toxin protocol (100 units of botulinum toxin diluted in 4 cc of saline) works superficially in the dermis to decrease melanocyte dendricity and prevent UV-induced pigment transfer, while the intradermal tranexamic acid acts as an anti-fibrinolytic and anti-angiogenic agent by blocking UV-induced plasminogen activity, paracrine melanocytic factors, and vascular growth factors (VEGF/endothelin-1). To further break down pigment and minimize post-inflammatory hyperpigmentation, Dr. Vieira employs a four-step Fotona pico-nano Nd:YAG laser protocol (targeting inflammation, pigment fragmentation, dermal remodeling via FracTAT, and vascularity) combined with laser-assisted drug delivery of a regenerative cocktail containing PDRN, glutathione, and topical antioxidants. She prepares patients’ skin barrier two weeks pre-procedure with topical ceramides and oral/IV antioxidant support, including Polypodium leucotomos, superoxide dismutase (GliSODin), and a post-laser glutathione IV push, emphasizing that lasting clearance requires treating the patient as a whole.
Julie Bass Kaplan, FNP-BC, CANS, presented an advanced, anatomically-grounded lecture on achieving 3D precision and safety in aesthetic injections, illustrating that successful outcomes depend on meticulous depth mapping and product selection. She compared the six available Type A neuromodulators to siblings with distinct “personalities,” contrasting high-precision, low-spread options like Letybo (ideal for the mentalis and DAO to prevent accidental diffusion into the adjacent DLI) with high-spread options like Dysport (best for broad foreheads). To maximize efficacy and avoid lid ptosis, she recommends using a concentrated 1 mL dilution and injecting directly at the glabella’s muscle origins and insertions in the hairy brow, employing a superficial dermal blanching technique in the lateral corrugators to create a visible white wheal. Kaplan outlined her clinical “sag line” (the middle frontal septum), advising injectors to place deep boluses on bone above this landmark and transition to superficial intradermal injections below it to prevent dropping the brow. For dermal fillers, she warned against placing deep needle boluses in the pre-jowl sulcus due to the overlapping origins of the DAO and DLI, which leads to intramuscular placement and a compromised smile. To prevent vascular occlusions—recounting her own severe 2010 facial occlusion from a sharp needle hitting an accessory foramen—she advocates for scraping the periosteum using a blunt-tip cannula deeply, or executing retrograde subdermal threading where the “popcorn ceiling” texture of the deep dermis ensures proper placement and stimulates localized estrogen release.
Dr. Francesca Lewis presented a comprehensive root-cause algorithm to load the dermatological toolbox for resolving both scarring (such as lichen planopilaris and frontal fibrosing alopecia) and non-scarring hair loss (like chronic telogen effluvium and androgenetic alopecia). Emphasizing that hair loss is a systemic manifestation of interconnected immune, metabolic, hormonal, and environmental factors, she detailed an extensive laboratory evaluation that evaluates free T3, free T4, thyroid antibodies (critical for identifying Hashimoto’s in patients with normal TSH), sex hormone binding globulin, free testosterone, DHT, and morning cortisol curves. To uncover hidden nutritional and metabolic drivers, she checks parameters like ferritin (targeting 40-70 ng/mL), vitamin D (targeting 60-80 ng/mL), zinc (targeting 80-100 mcg/dL), RBC magnesium, folate, methyl-B12, and HbA1c to compute HOMA-IR, alongside microbiome GI Maps, organic acid testing for mitochondrial function, and pharmacogenetic oral swabs. Crucially, she detailed how Mast Cell Activation Syndrome (MCAS) acts as a major, underdiagnosed driver of alopecia; histologic studies link increased mast cell concentrations to lichen planopilaris, frontal fibrosing alopecia, and alopecia areata, where mast cell-derived TGF-beta1 drives the micro-inflammatory cascades resulting in tissue fibrosis. Highlighting the clinical significance of contact allergies, Dr. Lewis reported that LPP patients exhibit patch test positivity rates near 80%, particularly to fragrance derivatives, benzyl alcohol, and sodium benzoate, warning that standard Kenalog and saline preparations formulated with these benzoic preservatives can trigger severe inflammatory hair loss flares if injected into allergic scalps. To combat these multifactorial drivers, her treatment framework incorporates an anti-inflammatory Mediterranean or autoimmune diet, stress/sleep hygiene, targeted mast-cell stabilizers (such as quercetin, luteolin, and high-dose vitamin C), and low-dose naltrexone (LDN) as a potent anti-inflammatory gamechanger, synergized with topical copper peptides, essential oils (thyme, lavender, rosemary, and cedarwood), oral androgen blockers, and structured PRP sessions spaced monthly for three months followed by maintenance.
Moderated by Dr. Sheila Farhang, this interactive panel addressed the dramatic clinical shifts induced by glucagon-like peptide-1 (GLP-1) receptor agonists, noting that the rapid weight loss triggers a 9% median midfacial superficial fat-pad volume decrease (with 10 kg of weight loss corresponding to a 7% loss) alongside severe nutritional telogen effluvium hair shedding from protein malnutrition. To successfully manage these aesthetic changes, the panel urged clinicians to break down historical procedural silos and establish a structured, journey-centered continuum that begins skin-tightening and bio-stimulatory procedures (such as radiofrequency microneedling and Poly-L-Lactic Acid) right when the patient initiates weight loss rather than waiting until the end of the active phase. Dr. Farhang shared her clinical guideline of administering one vial of PLLA (Sculptra) per ten pounds of anticipated weight loss, while the surgeons reassured that conservative PLLA biostimulation (such as one vial upper and one vial lower face annually) does not compromise future surgical facelifts. Dr. Duco detailed their multi-layer ‘Harmony’ approach, which stacks deep structural and volume support in Layer 1 (using PLLA or hyperdilute calcium hydroxylapatite), dermal collagen and quality tightening in Layer 2 (using RF microneedling or mechanical microneedling with PRF or exosome glides), and epidermal textural refinement in Layer 3 (using gentle chemical peels to prevent pigment rebound in melasma). Emphasizing long-term metabolic stability, the panel highlighted the necessity of lifestyle and nutritional tracking, using tools like dietary photo-logging apps (Lumen), wearables (Oura rings), and advanced scales (Hume scale) to secure adequate protein intake, manage visceral fat, and preserve bone density, ultimately helping patients transition safely into maintenance micro-dosing and prevent rebound.
Dr. Doris Day delivered a cellular-level lecture on transitioning aesthetic dermatology from superficial correction and rejuvenation toward skin longevity by targeting the fibroblast—the essential cell governing collagen synthesis, wound healing, paracrine signaling, and tissue regeneration. As fibroblasts age, they transition from highly efficient cells to exhausted and senescent states, secreting a contagious, pro-inflammatory senescence-associated secretory phenotype (SASP) that triggers sterile inflammation (DAMPs) and matrix degradation; she cautioned that hyper-stimulating these exhausted cells with aggressive energy settings or prescription retinoic acid in older skin can bypass the beneficial hormetic zone and accelerate cellular senescence. To extend the cellular longevity zone, she introduced the mechanistic target of rapamycin (mTor) as the evolutionarily preserved master regulator of aging, showing that selective Topical Torque 1 inhibitors (such as Req) can safely reset fibroblasts to a younger state without disrupting the vital epidermal skin barrier, which occurs during full Torque 1 and Torque 2 blockades from systemic rapamycin. Because the decline of estrogen in perimenopause and menopause results in up to 30% collagen loss within the first five years, Dr. Day highlighted that estrogen acts as a master coordinator of cutaneous NAD+ availability, which in turn drives sirtuins and AMPK to initiate autophagy, mitochondrial repair, and cellular housekeeping. Her clinical protocol utilizes topical estrogen to target high-density facial and scalp estrogen-beta receptors with minimal systemic absorption, transitions patients from irritating retinoic acid to gentle retinols combined with antioxidants, and integrates a structured, calendar-based annual treatment plan supported by resistance training, dietary protein, and targeted oral supplements (such as creatine monohydrate at 5-15g/day, hydrolyzed collagen peptides, urolithin A, astaxanthin, omega-3 with CoQ10, and bedtime magnesium glycinate/L-threonate) to achieve robust, future-proofed skin health.
Dr. Christy Prendergast introduced the emerging field of regenerative aesthetics, highlighting a cultural shift away from overfilled “pillow face” looks toward undetectable, preventative, and biology-driven treatments focused on cellular longevity and skin quality. As a premium therapeutic in this space, the Acorn platform utilizes a non-surgical harvest of 50 to 75 of the patient’s own hair follicles to cryopreserve, culture, and expand their cells into an autologous, 100% biocompatible topical secretome (“Acorn Secret”). This fully customized, cell-free formulation delivers five billion growth factors rich in procollagen cargo of the epidermal lineage, outperforming traditional platelet-rich plasma (PRP) in biological activity and clinical consistency. When applied topically following micro-needling or CO2 laser resurfacing, the secretome downregulates cutaneous inflammation and UV-induced cellular damage—safely and predictably reducing erythema and spot counts while significantly driving long-term patient retention and practice trust.
Mark Berto presented the Chrysalis TCA peel, a medically supervised, European-registered system that redefines the peel category by combining deep dermal stimulation with concurrent recovery support. This biphasic, pain-free protocol utilizes a unique “theater-style” mix of a shelf-stable acid component (Iconic) and a refrigerated active component (Neothesis), freshly blended before application to target conditions ranging from active acne to deep photoaging. Unlike traditional medium-depth peels that cause visible sheeting or molting, the Chrysalis peel triggers micronized, invisible exfoliation at the cellular level, leaving patients with a dewy, hydrated glow and immediately calm skin. The recovery phase delivers powerful anti-inflammatories, antimicrobials, and barrier-support agents—including phytosphingosine, phytic acid, ferulic acid, and hydrolyzed glycosaminoglycans—to promote progressive collagen and elastin remodeling over a standard four-treatment annual sequence.
Wendy Picket, RN, opened her session by advocating for a paradigm shift away from archaic, high-volume “quick fixes” and cookie-cutter filler protocols that cause overfilled, distorted faces toward a modern approach centered on long-term, cellular-based skin health and natural rejuvenation. She emphasized the clinical power of “synergistic stacking”—combining multiple modalities like PDO threads, PRF, biostimulators, and light-based lasers in a single treatment session to achieve highly efficient, maximum regenerative outcomes. Rather than spacing out treatments, doing them together provides dramatic results, which she demonstrated through clinical cases including under-eye PRF Easy Gel, a specialized cannula-based neck protocol combining diluted Radiesse, hyaluronic acid, and neuromodulators, and hand rejuvenation combining Radiesse with PRF. Ultimately, she stressed that long-term patient retention is built on patient education, precise anatomical assessment, multi-layered protocols, and nurturing deep integrative relationships that treat the whole patient from the inside out and outside in.
Dr. Sheila Farhang presented her layered facial rejuvenation framework, warning clinicians to prioritize predictability, safety, and evidence-backed protocols over unverified “signature” mixing trends. She outlined a strategic order of operations, preferring to use energy-based devices like RF microneedling, fractionated CO2, or microcoring first to tighten the skin before placing fillers or biostimulators, though noting that fillers can be used first if immediate patient satisfaction is required. Dr. Farhang detailed her highly effective under-eye corrective protocol for treating poorly placed tear trough filler, which involves completely dissolving the product with hyaluronidase, followed by three monthly sessions of RF microneedling to tighten laxity and increase lymphatic vessel drainage, and finishing with PRF Easy Gel to heal the skin before refilling conservatively. She concluded by emphasizing that practitioners must know their anatomical and device limitations, particularly when managing menopausal skin quality or extreme weight loss, to set realistic expectations and deliver harmonious, undetectable results.
Dr. Kalpna Duray Raj highlighted the rapid rise of GLP-1 receptor agonists and the resulting aesthetic challenge of “Ozempic face,” where accelerated weight loss causes up to a 20% loss of superficial and deep facial fat pads, leading to a gaunt, drooping appearance. To combat this lipoatrophy, she detailed her “Midface Miracle Lift,” an open-access study protocol of 30 patients utilizing a multi-depth, retrograde injection technique with hyperdilute calcium hydroxylapatite (CaHA/Radiesse) at 1:1 to 1:3 dilutions. This technique targets three distinct levels—periosteum, deep dermis, and fat pads—to globally recruit fibroblasts, triggering a massive 200% increase in elastin, a 75% boost in hydrating proteoglycans, and a surge in angiogenesis. Dr. Raj emphasized that this non-filler treatment safely restores structural ligament strength, cheek projection, and skin elasticity, providing a highly effective facial maintenance program that clinicians should pair with in-office GLP-1 management to prevent facial wasting throughout a patient’s weight loss journey.
Valerie Stern, SDPA, emphasized the critical importance of pre-procedural systemic health optimization, arguing that because cosmetic treatments are elective, clinicians must prepare the patient’s internal biology to ensure rapid wound healing and avoid devastating complications like delayed recovery, prolonged erythema, or post-inflammatory hyperpigmentation. She explained that cellular healing is heavily influenced by systemic factors like inflammatory burdens, pro-inflammatory cytokines, glycemic control, chronic stress, and poor sleep, which elevate cortisol, impair mitochondrial function, and reduce angiogenesis. To optimize outcomes, Stern implements evidence-informed pre-care protocols two to six weeks prior to procedures, advising patients to follow an anti-inflammatory diet, consume 1.0 to 1.5 grams of protein per kilogram daily to support collagen synthesis, sleep seven to nine hours, and employ stress-reduction techniques like box breathing. She concluded that treating underlying metabolic dysfunction and clinical inflammation first ensures a superior dermal canvas, faster recovery times, and significantly higher patient satisfaction.
Dr. Melissa Grill Peterson introduced peptide therapy as a cornerstone of personalized longevity medicine, defining peptides as intelligent, endogenous signaling molecules that act as cellular instructions to regulate biological aging and tissue repair. She highlighted research demonstrating that precision, lower-dose GLP-1 protocols achieved superior weight loss in half the time compared to standard clinical trials, completely avoiding side effects, muscle wasting, and facial lipoatrophy. Dr. Peterson detailed specific peptide applications to optimize the cellular environment, including Mitocoll (MC) for mitochondrial signaling and AMPK/mTor modulation, growth hormone-releasing analogs (Tesamorelin and Sermorelin) to preserve lean muscle, and GHK-Cu (copper peptide) to remodel the extracellular matrix and accelerate deep wound healing. She urged practitioners to move beyond simple outward treatments and instead focus on foundational cellular health, receptor site sensitivity, and microvascular blood flow to truly maximize regenerative aesthetic outcomes.
Lindsay Bright, NP, advocated for a holistic, three-dimensional approach to facial balancing, arguing that the lower third of the face (the chin, pre-jowl sulcus, and marionette lines) must be treated as a structural foundation rather than an optional refinement. She introduced her signature lower-face technique, which combines subcision-style “subsizing” of the pre-jowl tissue with a superficial, retrograde cannula-based filler placement across the marionette zone to create a seamless, youthful transition without adding heavy bulk or worsening jowling. Bright emphasized that successful outcomes require a deep understanding of filler rheology, G-prime, and cross-linking (BDDE) to select dynamic products that move naturally with the face, warning against static, cookie-cutter single-product applications. She concluded that by conducting dynamic assessments of patients in motion and educating them on managing light and shadow rather than injecting raw units, clinicians can deliver undetectable, elegant facial harmony that builds long-term practice growth.
Dr. Johnny Franco approached aesthetic technology through the idea of a treatment journey rather than a single device or procedure. With more patients experiencing significant weight loss, often at younger ages, he emphasized first identifying what has actually changed, skin laxity, volume, surface quality, cellulite, and body contour, and determining which concerns may respond to nonsurgical treatment and which still require surgery. A recurring theme was the value of starting the conversation early. Rather than waiting until patients finish losing weight to address aesthetic changes, he discussed being proactive while setting realistic expectations, particularly because skin tightening remains an active process while weight loss is ongoing. Instead of relying on one technology, he encouraged thinking in layers and combining approaches to address skin laxity, volume, cellulite, and other concerns based on what will make the greatest difference for that individual patient. Dr. Franco also stressed the importance of giving patients a clear roadmap. In his practice, treatment plans may be mapped over six, nine, or twelve months, prioritizing what matters most while allowing additional treatments to be added over time. He emphasized that the entire office team should understand that journey so patients receive consistent guidance from consultation through follow-up. His closing advice was to evaluate each layer of the concern, recognize that nonsurgical options continue to expand, and build a thoughtful treatment plan rather than treating what may be only one part of the problem.
Yvonne Dellos delivered a deeply personal talk on presence and leadership in aesthetic practice, opening with her own story of homelessness at age 14 and finding stability through a nurse practitioner, who saw her as a person rather than a chart—an encounter she credits with changing the trajectory of her life and shaping her belief that providers are “building people, not businesses.” She illustrated this philosophy through a story about a young model who came in for lip filler at her mother’s suggestion, describing how sitting fully present with the patient revealed the emotional weight behind a seemingly cosmetic request, and framed the resulting transformation as a privilege to alter someone’s self-image rather than a transaction. Drawing on this experience, she argued that leadership is defined by behavior and energy rather than title, using an anecdote about coaching a colleague through team friction to make the point that presence and “essence” communicate far more than words, and encouraged the audience to treat every patient and colleague interaction as an act of service and influence. People’s feelings after an encounter, not clinical volume or revenue, is the true measure of a practice’s success and legacy.
BEST PRICING ENDS SOON
